Session Chair Profile
Biography
Nadeem is the Founder and President of the Eisai Center for Genetics Guided Dementia Discovery (G2D2) – an autonomous “spin-in” biotech exclusively focused on harnessing human genetics, data sciences, and precision chemistry. G2D2 is located at a new, tailored-designed 50,000 Sqft facility in Cambridge, MA. Nadeem sits on the US National Academies of Science, Engineering and Medicine’s Roundtable on Genomics & Precision Health (within which he co-leads the Precision Therapeutics working group), and has served as Chair - US Institute of Medicine Workshop on “Drug Discovery From Genetic Bioresources”; Chair - World CNS Summit; Chair - Festival of Genomics; Chair - External Advisory Board, NIA Longevity Genomics Study; Industry Lead - ADNI Genetics; and Scientific Board, IMI-EPAD. Before joining Eisai, Nadeem was Senior Director, Head of Population Research & Head of Cardiometabolic Genetics, at Pfizer Inc. Prior to working in the pharmaceutical industry, Nadeem was tenured faculty at the School of Clinical Medicine, University of Cambridge (UK).
Session Abstract – PMWC 2020 Silicon Valley
The vast majority of available genomic data is from participants that are of white, European ancestry, therefore representing a fraction of the world’s population only. Continued disproportionate advances in genome sciences will exacerbate global healthcare disparities in several ways. This session will address how coordinated, multi-sector solutions could address and preempt such disparities to ensure the promise of precision medicines is realized globally.